Literature DB >> 23599666

Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.

Tamara Goldberg, Evangelina Berrios-Colon.   

Abstract

Entities:  

Year:  2013        PMID： 23599666      PMCID： PMC3628169     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  15 in total

1.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

2.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

3.  Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Authors:  Elahe A Mostaghel; Brett T Marck; Stephen R Plymate; Robert L Vessella; Stephen Balk; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

4.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Authors:  G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

5.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

Authors:  Daniel C Danila; Michael J Morris; Johann S de Bono; Charles J Ryan; Samuel R Denmeade; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Thian Kheoh; Christopher Haqq; Arturo Molina; Aseem Anand; Michael Koscuiszka; Steve M Larson; Lawrence H Schwartz; Martin Fleisher; Howard I Scher
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

6.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

Authors:  Alison H M Reid; Gerhardt Attard; Daniel C Danila; Nikhil Babu Oommen; David Olmos; Peter C Fong; L Rhoda Molife; Joanne Hunt; Christina Messiou; Christopher Parker; David Dearnaley; Joost F Swennenhuis; Leon W M M Terstappen; Gloria Lee; Thian Kheoh; Arturo Molina; Charles J Ryan; Eric Small; Howard I Scher; Johann S de Bono
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

7.  Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals.

Authors:  E A Platz; E B Rimm; W C Willett; P W Kantoff; E Giovannucci
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

Review 8.  Targeting the androgen receptor pathway in prostate cancer.

Authors:  Yu Chen; Charles L Sawyers; Howard I Scher
Journal:  Curr Opin Pharmacol       Date:  2008-08-12       Impact factor: 5.547

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531
View more
  8 in total

1.  Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.

Authors:  Mark C Markowski; Kevin D Frick; James R Eshleman; Jun Luo; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2016-07-12       Impact factor: 4.104

2.  Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats.

Authors:  Bianca Facchim Gonçalves; Silvana Gisele Pegorin de Campos; Wagner José Fávaro; Joyce Zalotti Brandt; Cristiane Figueiredo Pinho; Luis Antônio Justulin; Sebastião Roberto Taboga; Wellerson Rodrigo Scarano
Journal:  Horm Cancer       Date:  2018-01-23       Impact factor: 3.869

Review 3.  Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone.

Authors:  Samuel Dubinsky; Alia Thawer; Anne G McLeod; Thomas R J McFarlane; Urban Emmenegger
Journal:  Support Care Cancer       Date:  2019-05-10       Impact factor: 3.603

4.  Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.

Authors:  Kim Stuyckens; Fred Saad; Xu Steven Xu; Charles J Ryan; Matthew R Smith; Thomas W Griffin; Margaret K Yu; An Vermeulen; Partha Nandy; Italo Poggesi
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

5.  CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines.

Authors:  Alexandra Giatromanolaki; Virginia Fasoulaki; Dimitra Kalamida; Achilleas Mitrakas; Christos Kakouratos; Theodoros Lialiaris; Michael I Koukourakis
Journal:  Curr Urol       Date:  2019-11-13

6.  Abiraterone suppresses irradiated lung cancer cells-induced angiogenic capacities of endothelial cells.

Authors:  Tingyan Ruan; Liping Jiang; Junying Xu; Juying Zhou
Journal:  J Bioenerg Biomembr       Date:  2021-04-05       Impact factor: 2.945

7.  Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay.

Authors:  Marilena Colaianna; Sten Ilmjärv; Hedi Peterson; Ilse Kern; Stephanie Julien; Mathurin Baquié; Giorgia Pallocca; Sieto Bosgra; Agapios Sachinidis; Jan G Hengstler; Marcel Leist; Karl-Heinz Krause
Journal:  Arch Toxicol       Date:  2016-03-25       Impact factor: 5.153

Review 8.  FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.

Authors:  Aleksandra Sochacka-Ćwikła; Marcin Mączyński; Andrzej Regiec
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.